22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ADVERUM BIOTECHNOLOGIES INC. › 2024-2025

ADVERUM BIOTECHNOLOGIES INC. 2024-2025 Proxy Voting Records

At ADVERUM BIOTECHNOLOGIES INC.'s shareholder meeting held June 17, 2025, in the 2024-2025 proxy season, 86 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 535 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers as disclosed… — ADVERUM BIOTECHNOLOGIES INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ADVERUM BIOTECHNOLOGIES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ADVERUM BIOTECHNOLOGIES INC.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 7Ballot items
  • 86Asset managers
  • 535Fund votes
  • June 17, 2025Meeting date

Results at a glance

Meeting of June 17, 2025: 7 items on ADVERUM BIOTECHNOLOGIES INC.’s Form 8-K, filed June 18, 2025: 4 approved · 3 without a stated outcome.

Material dissent

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore ADVERUM BIOTECHNOLOGIES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ADVERUM BIOTECHNOLOGIES INC.

These tallies are ADVERUM BIOTECHNOLOGIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ADVERUM BIOTECHNOLOGIES INC. — official shareholder meeting results, meeting held June 17, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Laurent Fischer, M.D. 11,629,888---- 1,085,6484,170,898 91%Not verified—
Elect Director: Patrick Machado 11,449,705---- 1,265,8314,170,898 90%Not verified—
Elect Director: James Scopa 11,720,019---- 995,5174,170,898 92%Not verified—
. Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31 16,353,26320,296512,875 ---- 99.8%Approved—
. Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the compensation of Adverum's named executive officers as set forth in the Proxy Statement. The votes were 11,757,482745,415212,639 --4,170,898 94%Approved—
. Approval of the Amendment and Restatement of the 2024 Plan Adverum's stockholders approved the amendment and restatement of the 2024 Plan. The votes were 11,330,6631,194,133190,740 --4,170,898 90%Approved—
5. Approval of the Amendment of Certain Outstanding Stock Options to Reduce the Exercise Price Per Share as described in the Proxy Statement 9,442,6523,064,709208,175 --4,170,898 75%Approved—

Source: ADVERUM BIOTECHNOLOGIES INC., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.

How asset managers voted at the ADVERUM BIOTECHNOLOGIES INC. 2024-2025 meeting

Each item below shows how the 86 asset managers that disclosed a ADVERUM BIOTECHNOLOGIES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: James Scopa

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 11,720,019WITHHELD: 995,517
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class II Directors: James Scopa

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Elect Director: James Scopa”): 11,720,019 for, 995,517 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,138,612 for, 36,210 withheld, 8,180 abstained.

FOR
FOR: 2,138,612ABSTAIN: 8,180WITHHOLD: 36,210
Largest asset managers voting on “Election of Class II Directors: James Scopa” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard917,9290 00For
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock458,3150 00For
Charles Schwab49,0210 00For
QUANTITATIVE MASTER SERIES LLC33,7410 00For
Lincoln Financial16,5000 01,656Mixed
Equitable14,1210 03,600Mixed
Global X12,7300 00For
American Century00 011,423Withhold
Pacific Life11,4020 00For
Goldman Sachs11,2530 00For
Northern Trust10,8200 00For
AIG/SunAmerica00 010,627Withhold
Bridge Builder Trust9,2080 00For
Voya6,2810 00For
John Hancock00 5,1280Abstain
Prudential/PGIM00 02,690Withhold
Jackson National00 2,6560Abstain
Nationwide2,4580 00For
Calvert00 02,038Withhold
ProShares00 01,997Withhold
Victory Capital00 01,082Withhold
Brinker Capital Destinations Trust9850 00For
State Street9030 00For
PENN SERIES FUNDS INC8000 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

2. Elect Director: Laurent Fischer, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 11,629,888WITHHELD: 1,085,648
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class II Directors: Laurent Fischer, M.D.

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Elect Director: Laurent Fischer, M.D.”): 11,629,888 for, 1,085,648 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,131,392 for, 43,430 withheld, 8,180 abstained.

FOR
FOR: 2,131,392ABSTAIN: 8,180WITHHOLD: 43,430
Largest asset managers voting on “Election of Class II Directors: Laurent Fischer, M.D.” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard917,9290 00For
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock458,3150 00For
Charles Schwab49,0210 00For
QUANTITATIVE MASTER SERIES LLC33,7410 00For
Lincoln Financial16,5000 01,656Mixed
Equitable17,7210 00For
Global X12,7300 00For
American Century00 011,423Withhold
Pacific Life11,4020 00For
Goldman Sachs11,2530 00For
Northern Trust00 010,820Withhold
AIG/SunAmerica00 010,627Withhold
Bridge Builder Trust9,2080 00For
Voya6,2810 00For
John Hancock00 5,1280Abstain
Prudential/PGIM00 02,690Withhold
Jackson National00 2,6560Abstain
Nationwide2,4580 00For
Calvert00 02,038Withhold
ProShares00 01,997Withhold
Victory Capital00 01,082Withhold
Brinker Capital Destinations Trust9850 00For
State Street9030 00For
PENN SERIES FUNDS INC8000 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

3. Elect Director: Patrick Machado

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 11,449,705WITHHELD: 1,265,831
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: Election of Class II Directors: Patrick Machado

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Elect Director: Patrick Machado”): 11,449,705 for, 1,265,831 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,102,323 for, 72,499 withheld, 8,180 abstained.

FOR
FOR: 2,102,323ABSTAIN: 8,180WITHHOLD: 72,499
Largest asset managers voting on “Election of Class II Directors: Patrick Machado” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard917,9290 00For
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock458,3150 00For
Charles Schwab49,0210 00For
QUANTITATIVE MASTER SERIES LLC33,7410 00For
Lincoln Financial00 018,156Withhold
Equitable14,1210 03,600Mixed
Global X12,7300 00For
American Century00 011,423Withhold
Pacific Life11,4020 00For
Goldman Sachs11,2530 00For
Northern Trust00 010,820Withhold
AIG/SunAmerica00 010,627Withhold
Bridge Builder Trust9,2080 00For
Voya00 06,281Withhold
John Hancock00 5,1280Abstain
Prudential/PGIM00 02,690Withhold
Jackson National00 2,6560Abstain
Nationwide2,4580 00For
Calvert00 02,038Withhold
ProShares00 01,997Withhold
Victory Capital00 01,082Withhold
Brinker Capital Destinations Trust00 0985Withhold
State Street00 0903Withhold
PENN SERIES FUNDS INC00 0800Withhold

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

4. Approval of the Amendment of Certain Outstanding Stock Options to Reduce the Exercise Price Per Share as described in…

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

75% Approved · of votes cast

FOR 75%AGAINST
FOR: 9,442,652AGAINST: 3,064,709
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: To approve the amendment of certain outstanding stock options to reduce the exercise price per share to the closing price on the date of repricing.

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“5. Approval of the Amendment of Certain Outstanding Stock Options to Reduce the Exercise Price Per Share as described in the Proxy Statement”): 9,442,652 for, 3,064,709 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Adverum's stockholders approved the amendment of certain outstanding stock options to reduce the exercise price per share as described in the Proxy Statement.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 643,560 for, 1,539,442 against.

FORAGAINST
FOR: 643,560AGAINST: 1,539,442
Largest asset managers voting on “To approve the amendment of certain outstanding stock options to reduce the exercise price per share to the cl” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard0917,929 00Against
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock0458,315 00Against
Charles Schwab49,0210 00For
QUANTITATIVE MASTER SERIES LLC033,741 00Against
Lincoln Financial018,156 00Against
Equitable017,721 00Against
Global X12,7300 00For
American Century011,423 00Against
Pacific Life011,402 00Against
Goldman Sachs011,253 00Against
Northern Trust010,820 00Against
AIG/SunAmerica010,627 00Against
Bridge Builder Trust09,208 00Against
Voya06,281 00Against
John Hancock05,128 00Against
Prudential/PGIM02,690 00Against
Jackson National02,656 00Against
Nationwide02,458 00Against
Calvert02,038 00Against
ProShares01,997 00Against
Victory Capital01,082 00Against
Brinker Capital Destinations Trust0985 00Against
State Street0903 00Against
PENN SERIES FUNDS INC0800 00Against

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

5. . Approval of the Amendment and Restatement of the 2024 Plan Adverum's stockholders approved the amendment and…

Official resultCOMPENSATIONReported outcome: Approved

90% Approved · of votes cast

FOR 90%
FOR: 11,330,663AGAINST: 1,194,133
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: To approve the amendment and restatement of the Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan.

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Proposal 4: . Approval of the Amendment and Restatement of the 2024 Plan Adverum's stockholders approved the amendment and restatement of the 2024 Plan. The votes were as follows:”): 11,330,663 for, 1,194,133 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval of the Amendment and Restatement of the 2024 Plan Adverum's stockholders approved the amendment and restatement of the 2024 Plan.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of ADVERUM BIOTECHNOLOGIES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “To approve the amendment and restatemnent of the Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan.” (2 managers, 61,751 for).

The 29 asset managers below reported 2,028,983 for, 92,268 against.

FOR
FOR: 2,028,983AGAINST: 92,268
Largest asset managers voting on “To approve the amendment and restatement of the Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard917,9290 00For
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock458,3150 00For
QUANTITATIVE MASTER SERIES LLC33,7410 00For
Lincoln Financial018,156 00Against
Equitable14,1213,600 00Mixed
American Century011,423 00Against
Pacific Life11,4020 00For
Goldman Sachs011,253 00Against
Northern Trust010,820 00Against
AIG/SunAmerica010,627 00Against
Bridge Builder Trust9,2080 00For
Voya06,281 00Against
John Hancock05,128 00Against
Prudential/PGIM02,690 00Against
Jackson National02,656 00Against
Nationwide2,4580 00For
Calvert02,038 00Against
ProShares01,997 00Against
Victory Capital01,082 00Against
Brinker Capital Destinations Trust0985 00Against
State Street0903 00Against
PENN SERIES FUNDS INC0800 00Against
DWS0736 00Against
Allianz0396 00Against

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

6. . Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 11,757,482AGAINST: 745,415
Details: description as filed, official tally, votes by 86 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Proposal 3: . Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the compensation of Adverum's named executive officers as set forth in the Proxy Statement. T”): 11,757,482 for, 745,415 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Compensation of Named Executive Officers Adverum's stockholders approved, on an advisory basis, the compensation of Adverum's named executive officers as set forth in the Proxy Statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 31 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy s” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard917,9290 00For
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock458,3150 00For
Charles Schwab49,0210 00For
QUANTITATIVE MASTER SERIES LLC33,7410 00For
Lincoln Financial16,5001,656 00Mixed
Equitable14,1213,600 00Mixed
Global X12,7300 00For
American Century011,423 00Against
Pacific Life11,4020 00For
Goldman Sachs11,2530 00For
Northern Trust10,8200 00For
AIG/SunAmerica10,6270 00For
Bridge Builder Trust9,2080 00For
Voya6,2810 00For
John Hancock5,1280 00For
Prudential/PGIM02,690 00Against
Jackson National02,656 00Against
Nationwide2,4580 00For
Calvert02,038 00Against
ProShares1,9970 00For
Victory Capital1,0820 00For
Brinker Capital Destinations Trust9850 00For
State Street9030 00For
PENN SERIES FUNDS INC8000 00For

Fund voting reports, all 31 managers: 2,158,543 for, 24,459 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 66 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy s” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
TCG Crossover Management, LLC1,796,4820 00For
FRANKLIN ADVISERS INC1,639,1150 00For
5AM Venture Management, LLC541,6660 00For
Versant Venture Management, LLC506,8210 00For
BlackRock468,7330 00For
Goldman Sachs188,6420 00For
State Street162,06991 00For
Waverly Advisors, LLC160,1570 00For
Northern Trust85,0210 00For
Soleus Capital Management, L.P.67,3240 00For
Invesco049,439 00Against
Charles Schwab49,0210 00For
MELLON INVESTMENTS Corp36,1110 00For
Vanguard27,4120 00For
Dimensional014,103 00Against
American Century011,423 00Against
Rhumbline10,5235 00For
CAPTRUST FINANCIAL ADVISORS10,0000 00For
AQR9,6640 00For
JPMorgan09,414 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC8,9930 00For
Voya6,2810 00For
John Hancock5,1280 00For
FineMark National Bank & Trust5,0000 00For
BANK OF AMERICA NA4,7950 00For

Institutional-manager reports, all 66 managers: 5,823,965 for, 93,080 against. Showing the 25 largest; every one is in the interactive database (link above).

7. . Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the…

Official resultAUDIT-RELATEDReported outcome: Approved

99.8% Approved · of votes cast

FOR 99.8%
FOR: 16,353,263AGAINST: 20,296
Details: description as filed, official tally, votes by 31 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of our board of directors, of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025.

ADVERUM BIOTECHNOLOGIES INC.’s own tally for this item (“Proposal 2: . Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum ”): 16,353,263 for, 20,296 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of Selection of Independent Registered Public Accounting Firm Adverum's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 31 asset managers below reported 2,183,002 for.

FOR
FOR: 2,183,002
Largest asset managers voting on “To ratify the selection, by the Audit Committee of our board of directors, of Ernst & Young LLP as our indepen” at ADVERUM BIOTECHNOLOGIES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard917,9290 00For
FRANKLIN STRATEGIC SERIES581,8090 00For
BlackRock458,3150 00For
Charles Schwab49,0210 00For
QUANTITATIVE MASTER SERIES LLC33,7410 00For
Lincoln Financial18,1560 00For
Equitable17,7210 00For
Global X12,7300 00For
American Century11,4230 00For
Pacific Life11,4020 00For
Goldman Sachs11,2530 00For
Northern Trust10,8200 00For
AIG/SunAmerica10,6270 00For
Bridge Builder Trust9,2080 00For
Voya6,2810 00For
John Hancock5,1280 00For
Prudential/PGIM2,6900 00For
Jackson National2,6560 00For
Nationwide2,4580 00For
Calvert2,0380 00For
ProShares1,9970 00For
Victory Capital1,0820 00For
Brinker Capital Destinations Trust9850 00For
State Street9030 00For
PENN SERIES FUNDS INC8000 00For

Showing the 25 largest of 31 asset managers. All 31 are in the interactive database (link above).

Largest ADVERUM BIOTECHNOLOGIES INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 20,890,733 shares outstanding at the time of that meeting.

Fund voting reports: top ADVERUM BIOTECHNOLOGIES INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 4.39%
2FRANKLIN STRATEGIC SERIES 2.79%
3BlackRock 2.19%
4Charles Schwab 0.23%
5QUANTITATIVE MASTER SERIES LLC 0.16%
6Lincoln Financial 0.09%
7Equitable 0.08%
8Global X 0.06%
9American Century 0.05%
10Pacific Life 0.05%
Institutional-manager reports: top ADVERUM BIOTECHNOLOGIES INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers as disclosed…”, 2024-2025
#Asset manager % of shares outstanding
1TCG Crossover Management, LLC 8.60%
2FRANKLIN ADVISERS INC 7.85%
35AM Venture Management, LLC 2.59%
4Versant Venture Management, LLC 2.43%
5BlackRock 2.24%
6Goldman Sachs 0.90%
7State Street 0.78%
8Waverly Advisors, LLC 0.77%
9Northern Trust 0.41%
10Soleus Capital Management, L.P. 0.32%

Reported ADVERUM BIOTECHNOLOGIES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ADVERUM BIOTECHNOLOGIES INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
BML Investment Partners, L.P. 11.36% DEF14A
TCG Crossover Fund II, L.P. 9.94% DEF14A
TCG Crossover GP II, LLC 8.96% 13G
Entities affiliated with Franklin Advisers 8.43% DEF14A
Franklin Templeton 8.43% 13F
BlackRock 6.83% 13F
Augustus Stern 5.35% DEF14A
Principia Wealth Advisory, LLC 5.05% DEF14A
Rush Ryan Bradford 5.03% DEF14A
Entities affiliated with Frazer Life Sciences 4.99% DEF14A

Percentages above are of 20,890,733 shares outstanding, as reported by ADVERUM BIOTECHNOLOGIES INC. on its Form 10-Q dated May 6, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ADVERUM BIOTECHNOLOGIES INC.’s 10-Q dated May 6, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

ADVERUM BIOTECHNOLOGIES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Cite this page

proxyvotesnow.com, “ADVERUM BIOTECHNOLOGIES INC. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/adverum-biotechnologies-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.